(Q38031097)

27 August 2017

title

New pharmacotherapy for hepatitis C. (English)

1 reference

27 August 2017

0 references

D N Assis

1

1 reference

27 August 2017

J K Lim

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 August 2012

1 reference

Clinical Pharmacology & Therapeutics

27 August 2017

published in

1 reference

27 August 2017

volume

92

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

294-305

1 reference

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Steatosis: co-factor in other liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Clinical practice. Chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Redefining chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Gaps in the achievement of effectiveness of HCV treatment in national VA practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Hepatitis C: move over interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Insights into the role of interferon lambda in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

The natural history of hepatitis C cirrhosis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

Natural history of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

7 January 2021

Prospective study of plasma fibronectin in fulminant hepatitis: association with infection and mortality

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

7 January 2021

Genetic variations in heme oxygenase-1 and chronic hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

7 January 2021

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.103

7 January 2021

Identifiers

DOI

10.1038/CLPT.2012.103

1 reference

Dimensions Publication ID

27 August 2017

1045038038

0 references

1 reference